Sobi appoints Mats-Olof Wallin as interim Chief Financial Officer

Sobi appoints Mats-Olof Wallin as interim Chief Financial Officer 
STOCKHOLM, SWEDEN -- (Marketwired) -- 04/08/13 --  Mats-Olof Wallin
has been appointed interim Chief Financial Officer at Swedish Orphan
Biovitrum AB (Sobi). Wallin - until recently the CFO of Swedish
company Biotage AB (publ.) - brings more than 30 years of
experience in the pharmaceutical industry, gained from various
executive positions within companies such as Pharmacia, Ortivus and
Biotage. Wallin has been working at
Sobi for the past several months. 
"We are glad to welcome Mats-Olof as interim CFO.  Mats-Olof brings
experience to the role and will join our senior team in
building a sustainable
company which brings value to all
stakeholders", said CEO Geoffrey McDonough. 
Annika Muskantor, who has been interim CFO since August 2012, will
support Mats-Olof in his new role during a transition period. 
Continued McDonough: "I would like to thank Annika for her excellent
work the
past year. She has built a strong financial platform which
will continue to support the development of this company." 
About Sobi 
Sobi is an international specialty healthcare company dedicated to
rare diseases. Our mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily
focused on inflammation and genetic diseases,
with three late stage biological
development projects within
hemophilia and neonatology. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein
and biologics manufacturing. In 2012, Sobi had total
revenues of SEK 1.9 billion
(EUR 215 M) and about 480 employees. The
share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information
is available at 
Sobi press release April 8, 2013 in pdf version : 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE 
For more information - not for
Media relations
Oskar Bosson
Head of Communications
T: +46 70 410 71 80 
Investor relations
Jorgen Winroth
Vice President, Head of Investor Relations
T: +46 8 697 20 00
Press spacebar to pause and continue. Press esc to stop.